Trial Profile
Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tuberculosis DNA vaccine Ag85A (Primary) ; Tuberculosis DNA vaccine Ag85A
- Indications Tuberculosis
- Focus Adverse reactions
- 25 Oct 2021 Status changed from active, no longer recruiting to completed.
- 05 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2021 Planned End Date changed from 30 Sep 2021 to 30 Oct 2021.